Omalizumab for severe atopic keratoconjunctivitis
Omalizumab for severe atopic keratoconjunctivitis
复制标题
奥马珠单抗治疗严重特应性角结膜炎
作者：
C. Taillé;S. Doan;C. Neukirch;M. Aubier
1例35岁患者接受奥马珠单抗（300 mg，每月2次）治疗重度特应性角膜结膜炎（AKC）2年，以降低类固醇诱导的角膜炎风险。4个月后，生活质量和眼部症状改善，口服类固醇的使用大大减少。治疗耐受性良好。这一观察结果表明，奥马珠单抗可能是治疗重度AKC的良好选择，特别是为了避免免疫抑制治疗的副作用，如对其他过敏性疾病所建议的那样。应针对过敏性眼病设计专门的试验。
A 35-year-old patient received omalizumab (300 mg twice a month) for 2 years for a severe atopic keratoconjunctivitis (AKC) in order to reduce the risk for steroid-induced keratitis. After 4 months, quality of life and ocular symptoms improved, and the use of oral steroids was strongly reduced. The treatment was well tolerated. This observation suggests that omalizumab may be a good option for the treatment of severe AKC, especially to avoid side effects of immunosuppressive treatments, as suggested for other allergic diseases. Specific trials should be designed for allergic eye diseases.